Floatz logo

ROPIVACAINE

Renal Cancer

Meshalkin Research Institute of Pathology of CirculationSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Renal Cancer cohort.

Asset / SponsorPhaseRating
PROPOFOL
Seoul National University Hospital
Phase 4BB
Sevoflurane
Seoul National University Hospital
Phase 4BB
SUFENTANYL
Meshalkin Research Institute of Pathology of Circulation
Phase 4BB
Irinotecan
Toray Industries, Inc
Phase 2B
LIDOCAINE
University Hospital of Split
Phase 3B

View all 50 →

Same molecule, other indications

ROPIVACAINE is also rated in:

post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →
Knee Pain ChronicDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritis, hipDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →